Trial results

$PHAT — vonoprazan (VOQUEZNA)

Phathom Pharmaceuticals, Inc. (PHAT) vonoprazan (VOQUEZNA): trial results in Eosinophilic esophagitis (EoE), 2026.

Research by Catalyst Intel

The catalyst

"Topline results from the 12-week blinded treatment portion of the trial are expected to be reported during the fourth quarter of 2026."

— Phathom Pharmaceuticals, Inc., 10-Q filed 2026-10-29 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

PHAT-VONOPRAZANVO-2026

Company

Phathom Pharmaceuticals, Inc.

Kind

Trial results

Indication

Eosinophilic esophagitis (EoE)

Window

2026-01-01 – 2026-12-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.